An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare Providers

Pharmacogenetics can improve clinical outcomes by reducing adverse drug effects and enhancing therapeutic efficacy for commonly used drugs that treat a wide range of cardiovascular diseases. One of the major barriers to the clinical implementation of cardiovascular pharmacogenetics is limited education on this field for current healthcare providers and students. The abundance of pharmacogenetic literature underscores its promise, but it can also be challenging to learn such a wealth of information. Moreover, current clinical recommendations for cardiovascular pharmacogenetics can be confusing because they are outdated, incomplete, or inconsistent. A myriad of misconceptions about the promise and feasibility of cardiovascular pharmacogenetics among healthcare providers also has halted clinical implementation. Therefore, the main goal of this tutorial is to provide introductory education on the use of cardiovascular pharmacogenetics in clinical practice. The target audience is any healthcare provider (or student) with patients that use or have indications for cardiovascular drugs. This tutorial is organized into the following 6 steps: (1) understand basic concepts in pharmacogenetics; (2) gain foundational knowledge of cardiovascular pharmacogenetics; (3) learn the different organizations that release cardiovascular pharmacogenetic guidelines and recommendations; (4) know the current cardiovascular drugs/drug classes to focus on clinically and the supporting evidence; (5) discuss an example patient case of cardiovascular pharmacogenetics; and (6) develop an appreciation for emerging areas in cardiovascular pharmacogenetics. Ultimately, improved education among healthcare providers on cardiovascular pharmacogenetics will lead to a greater understanding for its potential in improving outcomes for a leading cause of morbidity and mortality.

[1]  A. Gaedigk,et al.  Advancing CYP2D6 Pharmacogenetics through a Pharmacoequity Lens , 2023, Clinical pharmacology and therapeutics.

[2]  H. Sabbah,et al.  Validation of a Polygenic Score for Beta-Blocker Survival Benefit in Patients With Heart Failure Using the United Kingdom Biobank. , 2023, Circulation Genomic and Precision Medicine.

[3]  M. Pirmohamed,et al.  A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study , 2023, The Lancet.

[4]  F. Moriarty,et al.  Direct-to-consumer genetic testing: an updated systematic review of healthcare professionals’ knowledge and views, and ethical and legal concerns , 2022, European Journal of Human Genetics.

[5]  C. Iribarren,et al.  Polygenic Risk Score and Statin Relative Risk Reduction for Primary Prevention of Myocardial Infarction in a Real‐World Population , 2022, Clinical pharmacology and therapeutics.

[6]  E. Ashley,et al.  Polygenic Risk Scores for Cardiovascular Disease: A Scientific Statement From the American Heart Association , 2022, Circulation.

[7]  M. Pirmohamed,et al.  Pharmacogenomics decision support in the U-PGx project: Results and advice from clinical implementation across seven European countries , 2022, PloS one.

[8]  L. Gong,et al.  The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin‐Associated Musculoskeletal Symptoms , 2022, Clinical pharmacology and therapeutics.

[9]  M. Farkouh,et al.  ABCD‐GENE Score and Clinical Outcomes Following Percutaneous Coronary Intervention: Insights from the TAILOR‐PCI Trial , 2022, Journal of the American Heart Association.

[10]  D. Voora,et al.  SLCO1B1*5 Allele Is Associated With Atorvastatin Discontinuation and Adverse Muscle Symptoms in the Context of Routine Care , 2022, Clinical pharmacology and therapeutics.

[11]  Yee Ming Lee,et al.  Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update , 2022, Clinical pharmacology and therapeutics.

[12]  Hao Li,et al.  Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA. , 2021, The New England journal of medicine.

[13]  D. Melzer,et al.  Statin treatment effectiveness and the SLCO1B1*5 reduced function genotype: Long‐term outcomes in women and men , 2021, medRxiv.

[14]  N. Risch,et al.  Effect of SLCO1B1 T521C on Statin‐Related Myotoxicity With Use of Lovastatin and Atorvastatin , 2021, Clinical pharmacology and therapeutics.

[15]  S. V. Van Driest,et al.  Moving Pharmacogenetics Into Practice: It’s All About the Evidence! , 2021, Clinical pharmacology and therapeutics.

[16]  L. Cavallari,et al.  Pharmacogenetics to guide cardiovascular drug therapy , 2021, Nature Reviews Cardiology.

[17]  V. Murthy,et al.  SEX-BASED DIFFERENCES IN CLINICAL OUTCOMES AFTER PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE TAILOR-PCI TRIAL , 2021 .

[18]  D. Stenehjem,et al.  Strategies and settings of clinical pharmacogenetic implementation: a scoping review of pharmacogenetics programs. , 2021, Pharmacogenomics.

[19]  Ebony B Madden,et al.  Establishing the Value of Genomics in Medicine – The IGNITE Pragmatic Trials Network , 2021, Genetics in Medicine.

[20]  K. Bailey,et al.  Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y12 Inhibitor Therapy: A Meta-Analysis. , 2021, JACC. Cardiovascular interventions.

[21]  T. Klein,et al.  Expanding evidence leads to new pharmacogenomics payer coverage , 2021, Genetics in Medicine.

[22]  G. Tison,et al.  Leveraging innovative technology to generate drug response phenotypes for the advancement of biomarker‐driven precision dosing , 2021, Clinical and translational science.

[23]  C. Formea,et al.  Considerations When Applying Pharmacogenomics to Your Practice. , 2020, Mayo Clinic proceedings.

[24]  Amy L. Pasternak,et al.  Prevalence and types of inconsistencies in clinical pharmacogenetic recommendations among major U.S. sources , 2020, npj Genomic Medicine.

[25]  R. Weinshilboum,et al.  A model-based cost-effectiveness analysis of pharmacogenomic panel testing in cardiovascular disease management: preemptive, reactive, or none? , 2020, Genetics in Medicine.

[26]  W. Kraus,et al.  Polygenic Score for β-Blocker Survival Benefit in European Ancestry Patients With Reduced Ejection Fraction Heart Failure , 2020, Circulation. Heart failure.

[27]  K. Bailey,et al.  Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. , 2020, JAMA.

[28]  A. Shatnawi,et al.  Pharmacogenomics Instruction Depth, Extent, and Perception in US Medical Curricula , 2020, Journal of medical education and curricular development.

[29]  Wenwen Du,et al.  Effects of ABCG2 and SLCO1B1 gene variants on inflammation markers in patients with hypercholesterolemia and diabetes mellitus treated with rosuvastatin , 2020, European Journal of Clinical Pharmacology.

[30]  M. Price,et al.  Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score. , 2020, JACC. Cardiovascular interventions.

[31]  M. Relling,et al.  The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later , 2019, Clinical pharmacology and therapeutics.

[32]  N. Limdi,et al.  Validation of the Spartan RXCYP2C19 Genotyping Assay Utilizing Blood Samples , 2019, Clinical and translational science.

[33]  G. Abecasis,et al.  Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial , 2019, Circulation.

[34]  M. Postma,et al.  A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI. , 2019, The New England journal of medicine.

[35]  K. Caudle,et al.  Ready or not, here it comes: Direct-to-consumer pharmacogenomic testing and its implications for community pharmacists. , 2019, Journal of the American Pharmacists Association : JAPhA.

[36]  P. Hulick,et al.  Pharmacogenomics: Prescribing Precisely. , 2019, The Medical clinics of North America.

[37]  Marco Valgimigli,et al.  Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. , 2019, JACC. Cardiovascular interventions.

[38]  Weidang Wu,et al.  The influence of genetic polymorphisms in drug metabolism enzymes and transporters on the pharmacokinetics of different fluvastatin formulations , 2019, Asian journal of pharmaceutical sciences.

[39]  Daniel E Forman,et al.  2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.

[40]  Ricardo L. Rojas,et al.  Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases , 2019, Genetics in Medicine.

[41]  N. Khanfar,et al.  A comparative study of the depth, breadth, and perception of pharmacogenomics instruction in a subgroup of US pharmacy curricula. , 2019, Currents in pharmacy teaching & learning.

[42]  L. Goldstein,et al.  Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association , 2019, Arteriosclerosis, thrombosis, and vascular biology.

[43]  Kristin A. Maloney,et al.  Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype‐Guided Antiplatelet Therapy , 2018, Clinical pharmacology and therapeutics.

[44]  N. Risch,et al.  Characterization of Statin Low-Density Lipoprotein Cholesterol Dose-Response Using Electronic Health Records in a Large Population-Based Cohort , 2018, Circulation. Genomic and precision medicine.

[45]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[46]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[47]  M. Hadamitzky,et al.  Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial , 2017, The Lancet.

[48]  Jeffrey L. Anderson,et al.  Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial , 2017, JAMA.

[49]  R. Altman,et al.  The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems , 2017, Clinical pharmacology and therapeutics.

[50]  Michelle E Klein,et al.  Clinical Implementation of Pharmacogenomics for Personalized Precision Medicine: Barriers and Solutions. , 2017, Journal of pharmaceutical sciences.

[51]  T E Klein,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update , 2017, Clinical pharmacology and therapeutics.

[52]  Mikael Hallstrøm Eriksen,et al.  Barriers and solutions , 2017 .

[53]  Meenakshi,et al.  Complementary feeding at 4 versus 6 months of age for preterm infants born at less than 34 weeks of gestation: a randomised, open-label, multicentre trial , 2017, The Lancet. Global health.

[54]  S. Herzig,et al.  Nondirected Testing for Inpatients With Severe Liver Injury , 2017, Journal of hospital medicine.

[55]  Dermot F. Reilly,et al.  Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting , 2017, Circulation.

[56]  S. Saini,et al.  Extensive testing or focused testing of patients with elevated liver enzymes. , 2017, Journal of hepatology.

[57]  J. Tenenbaum,et al.  Beyond the Genetic Information Nondiscrimination Act: ethical and economic implications of the exclusion of disability, long-term care and life insurance. , 2017, Personalized medicine.

[58]  L. Goh,et al.  Analysis of Genetic Variation in CYP450 Genes for Clinical Implementation , 2017, PloS one.

[59]  S. Johnston,et al.  Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis , 2017, Circulation.

[60]  J. Hoffman,et al.  Integrating pharmacogenomics into electronic health records with clinical decision support. , 2016, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[61]  M. Perez,et al.  Enhancing Literacy in Cardiovascular Genetics: A Scientific Statement From the American Heart Association , 2016, Circulation. Cardiovascular genetics.

[62]  M. Weale,et al.  Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? , 2016, The Pharmacogenomics Journal.

[63]  L. Dean Warfarin Therapy and the Genotypes CYP2C9 and VKORC1 , 2016 .

[64]  Yuan Ji,et al.  Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade. , 2016, The Journal of molecular diagnostics : JMD.

[65]  M. Luzum,et al.  Physicians' attitudes toward pharmacogenetic testing before and after pharmacogenetic education. , 2016, Personalized medicine.

[66]  S. Vegter,et al.  Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature , 2016, PloS one.

[67]  Diane Hauser,et al.  The IGNITE network: a model for genomic medicine implementation and research , 2015, BMC Medical Genomics.

[68]  U. Hofmann,et al.  Heritability of metoprolol and torsemide pharmacokinetics , 2015, Clinical pharmacology and therapeutics.

[69]  A. Jaffe,et al.  A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2015 .

[70]  K. Sangkuhl,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors , 2015, Clinical pharmacology and therapeutics.

[71]  Olle Melander,et al.  Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials , 2015, The Lancet.

[72]  F. Collins,et al.  A new initiative on precision medicine. , 2015, The New England journal of medicine.

[73]  R. Kittles,et al.  Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans , 2015, Pharmacogenetics and genomics.

[74]  M. Fornage,et al.  Basic concepts and potential applications of genetics and genomics for cardiovascular and stroke clinicians: a scientific statement from the American Heart Association. , 2015, Circulation. Cardiovascular genetics.

[75]  Teri E Klein,et al.  Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. , 2015, Annual review of pharmacology and toxicology.

[76]  L Gong,et al.  The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin‐Induced Myopathy: 2014 Update , 2014, Clinical pharmacology and therapeutics.

[77]  Anya E. R. Prince,et al.  Genetic Information, Non-Discrimination, and Privacy Protections in Genetic Counseling Practice , 2014, Journal of Genetic Counseling.

[78]  Munir Pirmohamed,et al.  A Randomized Trial of Genotype-Guided Dosing of Warfarin , 2014 .

[79]  R. Becker,et al.  Pharmacogenetics of Antiplatelet Therapy , 2014, Current Atherosclerosis Reports.

[80]  Aniwaa Owusu Obeng,et al.  Clinical pharmacogenetics implementation: Approaches, successes, and challenges , 2014, American journal of medical genetics. Part C, Seminars in medical genetics.

[81]  R. Califf,et al.  A pharmacogenetic versus a clinical algorithm for warfarin dosing. , 2013, The New England journal of medicine.

[82]  Erica A. Bowton,et al.  Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing , 2013, Clinical pharmacology and therapeutics.

[83]  R. Altman,et al.  Pharmacogenomics Knowledge for Personalized Medicine , 2012, Clinical pharmacology and therapeutics.

[84]  Edward O'Brien,et al.  Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial , 2012, The Lancet.

[85]  R. Verbrugge,et al.  Adoption of Pharmacogenomic Testing by US Physicians: Results of a Nationwide Survey , 2012, Clinical pharmacology and therapeutics.

[86]  G. Levine,et al.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Journal of the American College of Cardiology.

[87]  H. Guchelaar,et al.  Pharmacogenetics: From Bench to Byte— An Update of Guidelines , 2011, Clinical pharmacology and therapeutics.

[88]  Russell A. Wilke,et al.  Pharmacogenomics: The Genetics of Variable Drug Responses , 2011, Circulation.

[89]  A. Morris,et al.  Common Nonsynonymous Substitutions in SLCO1B1 Predispose to Statin Intolerance in Routinely Treated Individuals With Type 2 Diabetes: A Go‐DARTS Study , 2011, Clinical pharmacology and therapeutics.

[90]  R. Altman,et al.  Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. , 2010, The Lancet. Oncology.

[91]  T. Langaee,et al.  Genetic and Clinical Predictors of Warfarin Dose Requirements in African Americans , 2010, Clinical pharmacology and therapeutics.

[92]  G. Ginsburg,et al.  The SLCO1B1*5 genetic variant is associated with statin-induced side effects. , 2009, Journal of the American College of Cardiology.

[93]  J. Evans Recreational genomics; what's in it for you? , 2008, Genetics in Medicine.

[94]  R. Collins,et al.  SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.

[95]  F. Schmidt Meta-Analysis , 2008 .

[96]  D. Nebert,et al.  Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? , 1999, Clinical genetics.

[97]  H. Price Past and future , 1990, Nature.

[98]  Matthew J. Ferber,et al.  Direct‐to‐Consumer Testing 2.0: Emerging Models of Direct‐to‐Consumer Genetic Testing , 2018, Mayo Clinic proceedings.

[99]  Louis Valiquette,et al.  10 years later... , 2013, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

[100]  Russell A. Wilke,et al.  Genetics Primer for the General Cardiologist Pharmacogenomics The Genetics of Variable Drug Responses , 2011 .

[101]  S. Cohan It’s All about the Evidence , 2008 .

[102]  Abstr Act,et al.  SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study , 2008 .

[103]  W. Kalow The Pennsylvania State University College of Medicine 1990 Bernard B. Brodie Lecture. Pharmacogenetics: past and future. , 1990, Life sciences.

[104]  R. Knight,et al.  Comparison of isoniazid concentrations in the blood of people of Japanese and European descent; therapeutic and genetic implications. , 1958, American review of tuberculosis.

[105]  P. Freedson,et al.  Scientific Statement From the American Heart Association Guide to the Assessment of Physical Activity: Clinical and Research Applications: A , 2015 .